Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1789, Issue 5, 2009, Pages 422-431

  Monovich, Lauren ^a   Koch, Keith A ^b   Burgis, Robin ^a   Osimboni, Ekundayo ^a   Mann, Thierry ^a   Wall, Daniel ^a   Gao, Jinhai ^a   Feng, Yan ^a   Vega, Richard B ^a   Turner, Benjamin A ^b   Hood, David B ^b   Law, Andy ^b   Papst, Philip J ^b   Koditek, David ^b   Chapo, Joseph A ^b   Reid, Brian G ^b   Melvin, Lawrence S ^b   Pagratis, Nikos C ^b   McKinsey, Timothy A ^b  

^a Norvartis Institute for BioMedical Research   (United States)

^b Gilead Colorado Inc   (United States)

Author keywords

Cardiomyocyte; Histone deacetylase; Nuclear export; Signaling; Transcription

Indexed keywords

CYSTEINE; EXPORTIN 1; G PROTEIN COUPLED RECEPTOR; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; CARDIOMYOCYTE HYPERTROPHY; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; HEART MUSCLE CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPERTROPHY; INTRACELLULAR TRANSPORT; NEWBORN; NONHUMAN; NUCLEAR EXPORT; PHARMACOPHORE; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ACTIVE TRANSPORT, CELL NUCLEUS; AMIDES; ANILINE COMPOUNDS; ANIMALS; CARDIOMEGALY; CELL NUCLEUS; CELLS, CULTURED; HISTONE DEACETYLASES; HUMANS; KARYOPHERINS; MICROSCOPY, FLUORESCENCE; MYOCYTES, CARDIAC; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 67349179782     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.04.001     Document Type: Article

References (23)

1. Mann D.L., and Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111 (2005) 2837-2849
2. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., and Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114 (1991) 345-352
3. McKinsey T.A., and Kass D.A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 6 (2007) 617-635
4. Verdin E., Dequiedt F., and Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet. 19 (2003) 286-293
5. Yang X.J., and Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr. Opin. Genet. Dev. 13 (2003) 143-153
6. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., and Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell Biol. 24 (2004) 8467-8476
7. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N., and Class I.I. histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110 (2002) 479-488
8. Backs J., Song K., Bezprozvannaya S., Chang S., Olson E.N., and CaM kinase I.I. selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Invest 116 (2006) 1853-1864
9. McKinsey T.A. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc. Res. 73 (2007) 667-677
10. Harrison B.C., Roberts C.R., Hood D.B., Sweeney M., Gould J.M., Bush E.W., and McKinsey T.A. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol. Cell Biol. 24 (2004) 10636-10649
11. Harrison B.C., Kim M.S., van R.E., Plato C.F., Papst P.J., Vega R.B., McAnally J.A., Richardson J.A., Bassel-Duby R., Olson E.N., and McKinsey T.A. Regulation of cardiac stress signaling by protein kinase d1. Mol. Cell Biol. 26 (2006) 3875-3888
12. Vega R.B., Harrison B.C., Meadows E., Roberts C.R., Papst P.J., Olson E.N., and McKinsey T.A. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell Biol. 24 (2004) 8374-8385
13. Bush E., Fielitz J., Melvin L., Martinez-Arnold M., McKinsey T.A., Plichta R., and Olson E.N. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2870-2875
14. Ago T., Liu T., Zhai P., Chen W., Li H., Molkentin J.D., Vatner S.F., and Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133 (2008) 978-993
15. Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E.P., Wolff B., Yoshida M., Horinouchi S., and Leptomycin B. inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9112-9117
16. McKinsey T.A., Zhang C.L., and Olson E.N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14400-14405
17. Backs J., Backs T., Bezprozvannaya S., McKinsey T.A., and Olson E.N. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol. Cell Biol. 28 (2008) 3437-3445
18. Bossuyt J., Helmstadter K., Wu X., Clements-Jewery H., Haworth R.S., Avkiran M., Martin J.L., Pogwizd S.M., and Bers D.M. Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ. Res. 102 (2008) 695-702
19. Wu X., Zhang T., Bossuyt J., Li X., McKinsey T.A., Dedman J.R., Olson E.N., Chen J., Brown J.H., and Bers D.M. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J. Clin. Invest 116 (2006) 675-682
20. Zhang T., Kohlhaas M., Backs J., Mishra S., Phillips W., Dybkova N., Chang S., Ling H., Bers D.M., Maier L.S., Olson E.N., and Brown J.H. CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J. Biol. Chem. 282 (2007) 35078-35087
21. Daelemans D., Afonina E., Nilsson J., Werner G., Kjems J., De C.E., Pavlakis G.N., and Vandamme A.M. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14440-14445
22. Kau T.R., Schroeder F., Ramaswamy S., Wojciechowski C.L., Zhao J.J., Roberts T.M., Clardy J., Sellers W.R., and Silver P.A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4 (2003) 463-476
23. Liu J., and Defranco D.B. Protracted nuclear export of glucocorticoid receptor limits its turnover and does not require the exportin 1/CRM1-directed nuclear export pathway. Mol. Endocrinol. 14 (2000) 40-51